



Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Oct. 24, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the management team will participate in and attend one-on-one meetings at two investor conferences in November 2022 as follows:



Credit Suisse 31st Annual Healthcare Conference 2022

One-on-one meetings: Tuesday, November 8, 2022
Location: Rancho Palos Verdes, CA

Jefferies London Healthcare Conference 2022

Fireside Chat: November 15 at 2:40 pm GMT
One-on-one meetings: Tuesday, November 15, 2022
Location: London, UK

A webcast of the fireside chat will be available on the [News and Events](#) section of Gracell's investor website. A replay of the webcast will be available for 30 days following the event.

About Gracell

Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow [@GracellBio](#) on LinkedIn.

Media contact

Marvin Tang
marvin.tang@gracellbio.com

Investor contact

Gracie Tong
gracie.tong@gracellbio.com

 View original content to download multimedia: <https://www.prnewswire.com/news-releases/gracell-biotechnologies-to-participate-in-two-upcoming-investor-conferences-301656844.html>

SOURCE Gracell Biotechnologies Inc.